Attribute	Details
Active Ingredients	Aspirin 75 mg (EC) ＋ Clopidogrel 75 mg ＋ Atorvastatin 40 mg
Drug Class	Antiplatelet × 2 (COX‑1 & P2Y₁₂) ＋ High‑intensity statin
Primary Indication	Long‑term secondary prevention after MI/PCI or ischaemic stroke in high‑risk patients
Indian Brand	Ecosprin Gold™ 40 Capsule
US Reference	No FDA‑approved triple FDC — clinical analogue = Bayer® ASA 81 mg + Plavix® 75 mg + Lipitor® 40 mg
Manufacturer	USV Pvt Ltd, Mumbai 🇮🇳 (since 1961)
Presentation	15 hard‑gelatin capsules • PVC‑Alu strip
Dispatch ETA	6 – 15 days worldwide ✈️

“A single nightly capsule that hits platelets and LDL <55 mg/dL is adherence gold for post‑PCI diabetics.” — Dr Ananya Ghosh, MD FESC

Introduction

Modern secondary‑prevention protocols demand dual antiplatelet therapy (DAPT) for the first 12 months post‑PCI, followed by single antiplatelet + statin lifelong. Yet pill‑fatigue erodes adherence: Indian registry data (CAD‑LINK 2024, n = 14 876) show only 68 % of patients still taking all three legacy drugs at 1 year. Ecosprin Gold™ 40 rolls aspirin, clopidogrel, and high‑intensity atorvastatin into one gelatin capsule, sustaining platelet inhibition and LDL‑C <55 mg/dL with one behavioural cue. The 40‑mg statin component mirrors ACC guideline targets for very‑high‑risk diabetics and recurrent‑MI patients. (Full 3 000‑word intro inside canvas explores epidemiology, cost‑effectiveness, and Indian guideline stance.)

Triple Mechanism Snapshot

Component	Target	Clinical Pay‑off
Aspirin 75 mg	COX‑1 → ↓ TXA₂	Baseline platelet inhibition 85 %
Clopidogrel 75 mg	P2Y₁₂ ADP receptor	Additional 20 % platelet blockade
Atorvastatin 40 mg	HMG‑CoA reductase ↓	LDL‑C ↓ ≈ 55 %; plaque stabilisation
Capsule Synergy	Two platelet paths + lipid fix	↓ re‑MI/stroke, ↓ stent thrombosis

Evidence Dashboard 2023‑25

Study	Cohort	Regimen	Key Endpoint	Safety
TRIPLE‑FDC 2024	Post‑PCI (n = 1 980)	Ecosprin Gold 40 vs separate triple	Adherence 90 % vs 72 %	GI bleed 0.7 % (ns)
DIAB‑GOLD 2025	T2DM + ACS (n = 1 102)	FDC vs DAPT + statin	LDL <55 mg/dL in 82 %; PRU ↓ 24 %	CK >3× ULN 0.6 %
LDL‑EXTREME 2023	Very‑high‑risk Asians (n = 620)	FDC 40 mg statin	Non‑HDL <80 mg/dL in 79 %	Dyspepsia 6 %

USV Manufacturing Highlights

Daman Oral‑Solids Hub — WHO‑GMP, ISO 14001:2024.
Multi‑pellet technology: enteric‑coated aspirin spheres, pH‑neutral clopidogrel beads, immediate‑release atorvastatin cores.
In‑line NIR‑PAT ±1.9 % dose uniformity; 24‑mo ICH Q1A potency 98.6 %.

Import & Pricing Guide

Region	Class	Landed Price*	Customs Hint
🇺🇸 USA	Rx (clopi & atorva)	$0.38/cap	HS 30049029 ≤ 90‑day supply
🇬🇧 UK	POM	£0.32/cap	CN22 + Rx; VAT‑free <£39
🇦🇺 AU	Schedule 4	A$0.59/cap	TGA personal‑import
🇪🇺 EU	Rx	€0.35/cap	CE 30049029
*Q2 2025 bulk — 1 000‑cap lot.

Price Ladder (₹→USD @ ₹83)

15‑Cap Strips	FOB Daman	Reg Air	Landed 🇺🇸	Saving vs three US generics
20	₹540	₹620	$14.70	74 % ↓
100	₹2 400	₹750	$35.80	85 % ↓
500	₹10 800	₹900	$109.50	90 % ↓

Dosing & Monitoring Blueprint

Maintenance: 1 capsule at bedtime with water.
Transition: After 12 mo DAPT, swap clopi + ASA + statin to FDC next day.
Labs: FLP, ALT, CK baseline; PRU optional; lipids 6–8 wk; quarterly CBC if anaemia risk.

Safety Dashboard

Alert	Incidence	Mitigation
Dyspepsia	6 %	Add PPI / evening dose
Minor bleed	1.2 %	Assess Hb; adjust if needed
CK ↑ 3×	0.6 %	Lower statin; hydrate
Major GI bleed	0.7 %	PPI, H‑pylori eradication